TICKERNOMICS Sign up
Last Update: 2023-12-23 06:01:06
PRECIGEN INC. ( PGEN ) https://www.precigen.com
1.13USD
Sector:
Healthcare
Industry:
Biotechnology
Country:
United States
1y
3y
5y
10y
Historical Returns*:
SPY
23.45%
-19.29%
PGEN
SPY
30.72%
-88.60%
PGEN
SPY
112.82%
-83.95%
PGEN
SPY
201.04%
-94.53%
PGEN
*Assumes dividends reinvested
Market Stats:
Market Capitalization($MM)
Enterprise Value($MM)
Daily Volume(MM)
280.83
224.54
0.95
Valuation Metrics:
Price/Earnings Ratio
Price/Sales Ratio
Price/Book Value
FCF Yield(%)
Dividend Yield(%)
EV/EBITDA
12.68
12.71
1.90
-21.71
0.00
-3.48
Profitability Stats:
Operating Margin %(ttm)
Gross Profit %(ttm)
EBITDA Margin %(ttm)
-45.71
90.81
-291.83
Shareholder Value Creation:
Cost of Capital %(est)
ROIC %(ttm)
ROCE %(ttm)
Beta
10.07
67.87
-25.89
1.50
Other Earnings and Cash Flow Stats:
PRECIGEN INC. ( PGEN ) Net Income TTM ($MM) is 34.82
PRECIGEN INC. ( PGEN ) Operating Income TTM ($MM) is -60.53
PRECIGEN INC. ( PGEN ) Owners' Earnings Annual ($MM) is -90.00
PRECIGEN INC. ( PGEN ) Current Price to Owners' Earnings ratio is -3.38
PRECIGEN INC. ( PGEN ) EBITDA TTM ($MM) is -48.21
PRECIGEN INC. ( PGEN ) EBITDA Margin is -291.83%
Capital Allocation:
PRECIGEN INC. ( PGEN ) has paid 0.00 dividends per share and bought back -47.850134 million shares in the past 12 months
PRECIGEN INC. ( PGEN ) has reduced its debt by 1.588 million USD in the last 12 months
Capital Structure:
PRECIGEN INC. ( PGEN ) Interest-bearing Debt ($MM) as of last quarter is 7
PRECIGEN INC. ( PGEN ) Annual Working Capital Investments ($MM) are -26
PRECIGEN INC. ( PGEN ) Book Value ($MM) as of last quarter is 147
PRECIGEN INC. ( PGEN ) Debt/Capital as of last quarter is 5%
Other Balance Sheet Stats:
PRECIGEN INC. ( PGEN ) has 10 million in cash on hand as of last quarter
PRECIGEN INC. ( PGEN ) has 32 million of liabilities due within 12 months, and long term debt 13 as of last quarter
PRECIGEN INC. ( PGEN ) has 248 common shares outstanding as of last quarter
PRECIGEN INC. ( PGEN ) has 0 million USD of preferred stock value
Academic Scores:
PRECIGEN INC. ( PGEN ) Altman Z-Score is -11.05 as of last quarter
PRECIGEN INC. ( PGEN ) Piotroski Score is 5.00 as of last quarter
Corporate Governance:
PRECIGEN INC. ( PGEN ) largest shareholder is Renaissance Technologies Corp owning 1483590 shares at 1.68 ($MM) value
Dean J Mitchell(an insider) Bought 25000 shares of PRECIGEN INC. ( PGEN ) for the amount of $35250.00 on 2023-09-22
10.07% of PRECIGEN INC. ( PGEN ) is held by insiders, and 62.42% is held by institutions
PRECIGEN INC. ( PGEN ) went public on 2013-08-08
Other PRECIGEN INC. ( PGEN ) financial metrics:
FCF:-76.62
Unlevered Free Cash Flow:-101.71
EPS:1.41
Operating Margin:-45.71
Gross Profit Margin:90.81
Div. Payout Ratio%:0.00
Div. Growth YoY%:0.00
Equity Return%:236.67
Beta:1.50
Buffet's Owners Earnings:-90.00
Price to Owner's Earnings:-3.38
About PRECIGEN INC. ( PGEN ) :
Precigen, Inc. discovers and develops the next generation of gene and cellular therapies in the United States. The company operates through two segments, Biopharmaceuticals and Exemplar. It also provides disease-modifying therapeutics; genetically engineered swine for regenerative medicine applications; and reproductive technologies. In addition, the company offers UltraVector platform that incorporates advanced DNA construction technologies and computational models to design and assemble genetic components into complex gene expression programs; mbIL15, a gene that enhances functional characteristics of immune cells; Sleeping Beauty, a non-viral transposon/transposase system; AttSite recombinases, which breaks and rejoins DNA at specific sequences; AdenoVerse technology platform, a library of engineered adenovector serotypes; and Lactococcus lactis, a food-grade bacterium. Additionally, it provides RheoSwitch Therapeutic System, an inducible gene switch system that provides quantitative dose-proportionate regulation of the amount and timing of target protein expression; kill switches to selectively eliminate cell therapies in vivo; tissue-specific promoters; UltraCAR-T platform for the treatment of cancer; AdenoVerse Immunotherapy, a library of proprietary adenovectors for the gene delivery; and ActoBiotics platform, genetically modified bacteria that deliver proteins and peptides at mucosal sites. Precigen, Inc. has collaboration and license agreements with Alaunos Therapeutics, Inc.; Intrexon Energy Partners, LLC; and Intrexon Energy Partners II, LLC. The company was formerly known as Intrexon Corporation and changed its name to Precigen, Inc. in January 2020. Precigen, Inc. was founded in 1998 and is headquartered in Germantown, Maryland.
User Content from Tickernomics. Created by Luminus.
DISCLAIMER

This web site and its creators are not certified financial advisors. All opinions/suggestions expressed on this website should not be treated as specific inducement to make a particular investment or follow a particular strategy, but only as an expression of an opinion.The Company doesn't warrant the information provided on the website for its completeness or accuracy, and it should not be relied upon as such. The Company is not under any obligation to update or correct any information provided on this website.The content of this website is published in the United States of America and persons who access it agree to do so in accordance with applicable U.S. law.Past performance is not indicative of future results. The Company doesn't guarantee any specific outcome or profit. You should be aware of the real risk of loss in following any strategy or investment discussed on this website.Strategies or investments discussed may fluctuate in price or value. Investors may get back less than invested. Investments or strategies mentioned on this website may not be suitable for you. This material does not take into account your particular investment objectives,financial situation or needs and is not intended as recommendations appropriate for you. You must make an independent decision regarding investments or strategies mentioned on this website. Before acting on information on this website, you should consider whether it is suitable for your particular circumstances and strongly consider seeking advice from your own financial or investment adviser.